邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

碘难治性分化型甲状腺癌的诊治管理指南计划书(2023版)

温强,  王任飞,  黄蕤,  张越伦,  林岩松,  中国临床肿瘤学会核医学专家委员会

downloadPDF
文章导航 > 协和医学杂志  > 2023 >  14(6): 1197-1202
温强, 王任飞, 黄蕤, 张越伦, 林岩松, 中国临床肿瘤学会核医学专家委员会. 碘难治性分化型甲状腺癌的诊治管理指南计划书(2023版)[J]. 协和医学杂志, 2023, 14(6): 1197-1202. doi: 10.12290/xhyxzz.2023-0342
引用本文: 温强, 王任飞, 黄蕤, 张越伦, 林岩松, 中国临床肿瘤学会核医学专家委员会. 碘难治性分化型甲状腺癌的诊治管理指南计划书(2023版)[J]. 协和医学杂志, 2023, 14(6): 1197-1202. doi: 10.12290/xhyxzz.2023-0342
shu
WEN Qiang, WANG Renfei, HUANG Rui, ZHANG Yuelun, LIN Yansong, Chinese Society of Clinical Oncology Nuclear Medicine Expert Committee. Guidelines for the Diagnosis, Treatment, and Management of Iodine Refractory Differentiated Thyroid Cancer(2023 edition)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1197-1202. doi: 10.12290/xhyxzz.2023-0342
Citation: WEN Qiang, WANG Renfei, HUANG Rui, ZHANG Yuelun, LIN Yansong, Chinese Society of Clinical Oncology Nuclear Medicine Expert Committee. Guidelines for the Diagnosis, Treatment, and Management of Iodine Refractory Differentiated Thyroid Cancer(2023 edition)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1197-1202. doi: 10.12290/xhyxzz.2023-0342
shu

碘难治性分化型甲状腺癌的诊治管理指南计划书(2023版)

doi: 10.12290/xhyxzz.2023-0342
  • 1.

    吉林大学中日联谊医院核医学科, 长春 130033

  • 2.

    同济大学附属第十人民医院核医学科, 上海 200072

  • 3.

    四川大学华西医院核医学科, 成都 610041

  • 4.

    中国医学科学院北京协和医院医学科学研究中心, 北京 100730

  • 5.

    中国医学科学院北京协和医院核医学科, 北京 100730

基金项目: 

中央高水平医院临床科研专项 2022-PUMCH-B-072

详细信息
    通讯作者:

    林岩松, E-mail: Linys@pumch.cn

  • 中图分类号: R451;R736.1

Guidelines for the Diagnosis, Treatment, and Management of Iodine Refractory Differentiated Thyroid Cancer(2023 edition)

  • 1.

    Department of Nuclear Medicine, China-Japan Union Hospital, Jilin University, Changchun 130033, China

  • 2.

    Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China

  • 3.

    Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China

  • 4.

    Medical Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 5.

    Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds: 

National High Level Hospital Clinical Research Funding 2022-PUMCH-B-072

More Information

    摘要
  • 摘要: 为使我国碘难治性分化型甲状腺癌(radioiodine refractory differentiated thyroid cancer，RAIR-DTC)临床诊疗工作更加规范，迫切需要构建基于循证医学证据的临床诊治管理指南，以更加科学地指导和完善RAIR-DTC的日常诊疗工作。参照《世界卫生组织指南制订手册》，本研究团队注册并撰写了《碘难治性分化型甲状腺癌的诊治管理指南计划书(2023版)》，并将严格按照相关循证指南要求的制订流程制定和发布正式的指南文件。该计划书主要介绍了指南的制订目的、应用范围、使用者、目标人群、指南工作组成员、临床问题的收集与量化评价、证据筛选与质量评估以及推荐意见的产生与同行评审等内容。
    Abstract: To further standardize the clinical diagnosis and treatment decisions of radioiodine refractory differentiated thyroid cancer (RAIR-DTC) in China, it is urgent to establish clinical diagnosis and treatment management guidelines based on evidence-based medical data to scientifically guide the diagnosis and treatment of RAIR-DTC. By referring to the World Health Organization Guidelines Development Manual andfollowing the protocol of devising evidence-based guidelines, we have registered and written the prospectus of Guidelines for the Diagnosis, Treatment, and Management of Iodine Refractory Differentiated Thyroid Cancer. We will also develop and release official guidance documents. This guidelines prospectus mainly introduces the significance, purpose, target population, user population, guidelines formulation team members, collection and determination of clinical issues and outcome indicators, acquisition, evaluation, and synthesis of evidence, as well as generation of recommendations and other guidelines formulation methods and processes of the Guidelines for the Diagnosis, Treatment, and Management of Iodine Refractory Differentiated Thyroid Cancer.
    作者贡献：温强负责起草计划书及计划书注册; 王任飞负责绘图；黄蕤负责摘要翻译; 张越伦负责方法学指导; 林岩松负责项目整体运营及论文审核。
    利益冲突：所有作者均声明不存在利益冲突
    • HTML全文

  • 图  1  证据检索整体思路

    下载: 全尺寸图片 幻灯片
    • 参考文献(24)
  • [1] Zheng RS, Zhang SW, Zeng HM, et al. Cancer incidence and mortality in China, 2016[J]. J Nat Cancer Center, 2022, 2: 1-9. doi:  10.1016/j.jncc.2022.02.002
    [2] Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J]. Thyroid, 2016, 26: 1-133. doi:  10.1089/thy.2015.0020
    [3] 刘延晴, 林岩松. 碘难治性分化型甲状腺癌诊治策略及预后[J]. 中国实用外科杂志, 2019, 39: 216-220. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWK201903007.htm
    [4] 王任飞, 王勇, 石峰, 等. 碘难治性分化型甲状腺癌的诊治管理共识(2019年版)[J]. 中国癌症杂志, 2019, 29: 476-480. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ201906015.htm
    [5] Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy[J]. J Clin Endocrinol Metab, 2006, 91: 2892-2829. doi:  10.1210/jc.2005-2838
    [6] Robin G, Michelle M, Dianne MW, et al. Clinical Practice Guidelines We Can Trust[M]. Washington (DC): National Academies Press (US), 2011.
    [7] Brożek JL, Akl EA, Alonso CP, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines[J]. Allergy, 2009, 64: 669-677. doi:  10.1111/j.1398-9995.2009.01973.x
    [8] Howard B, Mark H, Holger JS, et al. GRADE guidelines: 3. Rating the quality of evidence[J]. J Clin Epidemiol, 2011, 64: 401-406. doi:  10.1016/j.jclinepi.2010.07.015
    [9] 拜争刚, 刘少堃, 黄崇斐, 等. 定性系统评价证据分级工具: CERQual简介[J]. 中国循证医学杂志, 2015, 15: 1465-1470. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ201512015.htm
    [10] Melissa CB, Michelle EK, George PB, et al. AGREE Ⅱ: advancing guideline development, reporting and evaluation in health care[J]. CMAJ, 2010, 182: E839-E842. doi:  10.1503/cmaj.090449
    [11] 张方圆, 沈傲梅, 马婷, 等. 中国癌症症状管理实践指南计划书[J]. 护理研究, 2018, 32: 8-12. https://www.cnki.com.cn/Article/CJFDTOTAL-SXHZ201801005.htm
    [12] Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ, 2008, 336: 924-926. doi:  10.1136/bmj.39489.470347.AD
    [13] Guyatt GH, Oxman AD, Kunz R, et al. GRADE指南: Ⅱ. 构建问题、确定重要结果[J]. 中国循证医学杂志, 2011, 11: 446-450. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ202112011.htm
    [14] Beverley JS, Barnaby CR, George W, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interven-tions, or both[J]. BMJ, 2017, 358: j4008.
    [15] 熊俊, 陈日新. 系统评价/Meta分析方法学质量的评价工具AMSTAR[J]. 中国循证医学杂志, 2011, 11: 1084-1089. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ201109016.htm
    [16] Chen Y, Yang K, Marušic A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement[J]. Ann Intern Med, 2017, 166: 128-132.
    [17] Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial[J]. Lancet, 2014, 384: 319-328. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60421-9/fulltext
    [18] Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J Med, 2015, 372: 621-630. https://pubmed.ncbi.nlm.nih.gov/25671254/
    [19] Chi Y, Gao M, Zhang Y, et al. Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase Ⅱ trial[J]. Ann Oncol, 2020, 31: S1347.
    [20] Lin YS, Qin SK, Yang H, et al. Multicenter Randomized Double-Blind Phase Ⅲ Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer[J]. Clin Cancer Res, 2023, 29: 2791-2799.
    [21] Lin Y, Qin S, Li Z, et al. Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial[J]. JAMA Oncol, 2021, 8: 242-250. https://pubmed.ncbi.nlm.nih.gov/34913959/
    [22] Chen J, Ji Q, Bai C, et al. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase Ⅱ Trial[J]. Thyroid, 2020, 30: 1245-1253.
    [23] Brose MS, Robinson BG, Sherman SI, et al. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial[J]. Cancer, 2022, 128: 4203-4212.
    [24] Alonso-Coello P, Oxman AD, Moberg J, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines[J]. BMJ, 2016, 353: i2089. https://pubmed.ncbi.nlm.nih.gov/27353417/
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
图(1)
计量
  • 文章访问数:  256
  • HTML全文浏览量:  187
  • PDF下载量:  136
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-07-23
  • 录用日期:  2023-08-02
  • 网络出版日期:  2023-08-22
  • 刊出日期:  2023-11-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！